Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 10/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL795346 | 0.83 | ATR (0.36) | ATRSTAT3HDAC4HDAC1HDAC6 | |
| SCHEMBL797277 | 0.81 | CASP3 (0.45) | STAT3S1PR1S1PR3S1PR5HDAC4 | |
| SCHEMBL795809 | 0.81 | MAPT (0.36) | ATRHPGDSHDAC1HDAC6 | |
| SCHEMBL794849 | 0.79 | GABRA5 (0.42) | HDAC4HPGDSHDAC1HDAC6 | |
| SCHEMBL15480817 | 0.78 | DHFR (0.36) | ATR | |
| SCHEMBL796459 | 0.77 | HDAC4 (0.33) | ATRS1PR1S1PR3HDAC4HDAC1 | |
| SCHEMBL796527 | 0.77 | GRM5 (0.38) | — | |
| SCHEMBL796056 | 0.76 | NPC1 (0.41) | S1PR1 | |
| SCHEMBL796822 | 0.75 | HCAR2 (0.33) | ATRS1PR1S1PR3HDAC4 | |
| SCHEMBL808016 | 0.75 | STAT3 (0.38) | STAT3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | ATR 3900/4885STAT3 1310/4885S1PR1 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.